about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

End­points 11 win­ner MediLink Ther­a­peu­tics: Chi­na start­up helps pow­er the ADC re­nais­sance

7 months ago
Startups
Special

FDA au­tho­rizes No­vavax Covid boost­er; Re­cur­sion nears key da­ta read­outs; What’s next for CD47?; and more

8 months ago
Weekly

Bio­Marin lays off 225 em­ploy­ees as it cuts spend­ing on gene ther­a­py roll­out

8 months ago
People
Pharma

Mubadala, CBC Group ink $680M deal for UCB’s neu­rol­o­gy and al­ler­gy port­fo­lio in Chi­na

8 months ago
Deals
China

Tome plans lay­offs amid strug­gle; FDA turns away Re­gen­eron; Next-gen obe­si­ty start­up launch­es; James Sabry joins ...

8 months ago
Weekly

Mer­ck re­jigs ADC deal with Kelun, grab­bing one pro­gram and re­turn­ing an­oth­er

8 months ago
Deals
R&D

BioN­Tech, MediLink to re­sume tri­al en­roll­ment for HER3 an­ti­body-drug con­ju­gate af­ter FDA pause

8 months ago
R&D
China

TYK Med­i­cines seeks to launch new EGFR drug in Chi­na with $74M Hong Kong IPO

8 months ago
Financing
China

Un­pack­ing IRA price ne­go­ti­a­tions re­sults; Lykos’ tough week; Genen­tech re­thinks can­cer im­munol­o­gy; and more

9 months ago
Weekly

Zealand joins next-gen club aim­ing to ‘ac­cel­er­ate’ obe­si­ty drug de­vel­op­ment

9 months ago
R&D

As­traZeneca's Imfinzi, Lyn­parza com­bo ap­proved in EU for cer­tain en­dome­tri­al can­cer pa­tients

9 months ago
Pharma

CSL Behring says up­take of he­mo­phil­ia B gene ther­a­py slow­er than ex­pect­ed

9 months ago
Pharma
Cell/Gene Tx

Lat­est on MD­MA re­jec­tion; No­vo vs. Lil­ly earn­ings; Re­cur­sion, Ex­sci­en­tia to merge; Q&A with Genen­tech CEO; and more

9 months ago
Weekly

En­tero Ther­a­peu­tics turns the lights off as cred­i­tors come call­ing

9 months ago
People

Bay­er de­tails 3,200 job cuts so far, spot­lights ‘mo­men­tum’ in phar­ma pipeline

9 months ago
Pharma

Bris­tol My­ers re­turns TIG­IT bis­pe­cif­ic to Agenus, frees it­self from $1B+ mile­stones

9 months ago
Deals
R&D

Ei­sai’s new Leqem­bi da­ta; Jim Wil­son’s next move; Roivant deal­mak­er’s pay­day; What’s next for MD­MA?; and more

9 months ago
Weekly

In Japan, sales of Ei­sai and Bio­gen's Alzheimer's drug be­gin to ac­cel­er­ate

9 months ago
Pharma

Up­dat­ed: Ot­su­ka buys out small mol­e­cule drug dis­cov­ery start­up Jnana and its rare dis­ease pill for $800M cash

9 months ago
Deals

Take­da takes $140M hit on Phase 3 epilep­sy flop, pre­views late-stage tri­als for pipeline prospects

9 months ago
R&D
Pharma

BioN­Tech, Re­gen­eron claim Phase 2 win for can­cer vac­cine, PD-1 com­bo

9 months ago
R&D

Ex­clu­sive: Start­up aims to tack­le ‘un­drug­gable’ neu­ro tar­gets with tech from Ke­van Shokat's UCSF lab

9 months ago
Financing
Startups

WuXi AppTec sees US rev­enue de­cline amid Biose­cure threat

9 months ago
China
Manufacturing

Map­ping GLP-1 game plans; Q2 earn­ings high­lights; J&J vets re­group at start­up; and more

9 months ago
Weekly
1234 Next page Last page
A service from the Financial Times